Shares of Affymetrix dropped 14.2 percent for the five-day trading period ended Tuesday. The firm’s shares fell 9.6 percent on Tuesday alone after it said it had filed a shelf registration to offer $250 million of senior convertible notes (see Briefs).
Canaccord Adams analyst Matthew Scalo speculated in an interview with Reuters that Affymetrix may be looking for a “sizeable acquisition.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.